Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany.
Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Cancer Med. 2021 Oct;10(20):7071-7078. doi: 10.1002/cam4.4237. Epub 2021 Aug 25.
In this survey, we analyzed data from patients suffering from the most common cutaneous T-cell lymphomas (CTCLs) subtypes mycosis fungoides (MF) and Sézary syndrome (SS), treated with the retinoid alitretinoin during a 7-year period at our outpatient department between 2015 and 2020.
We analyzed patient medical records including TNMB stage, side effects under therapy with alitretinoin, time to next treatment (TTNT), and previous photo documentation.
A total of 35 patients with MF (n = 28) and SS (n = 7) were included in the study, of whom 69% were male and 31% were female. The mean age of onset was 56 ± 15 years in MF and 65.4 ± 10.8 years in SS with 51.4% having early stage (IA-IIA) and 48.6% having advanced stage (IIB-IVA) CTCL. Of these patients 37.2% responded to alitretinoin, 28.6% had a stable course, and 34.3% experienced progression. Alitretinoin was administered as a monotherapy (25.7%) or combined with five concomitant therapies (74.2%), most frequently with ECP (31.4%) and PUVA (11.4%). 63% did not report any side effects, most often hypertriglyceridemia (20%) was described.
Considering that nearly two thirds of the CTCL patients treated with alitretinoin showed a response or stable disease, together with a low number of side effects and low cost compared to bexarotene, alitretinoin may be a potential alternative in the treatment of less advanced CTCLs. This survey represents the largest number of recorded therapies with the retinoid alitretinoin in CTCLs in a European patient collective.
在这项调查中，我们分析了 2015 年至 2020 年期间在我们门诊接受治疗的最常见皮肤 T 细胞淋巴瘤（CTCL）亚型蕈样真菌病（MF）和塞扎里综合征（SS）患者的数据。
我们分析了患者的病历，包括 TNMB 分期、阿利维 A 酯治疗的副作用、下一次治疗的时间（TTNT）和以前的照片记录。
共有 35 例 MF（n=28）和 SS（n=7）患者纳入研究，其中 69%为男性，31%为女性。MF 的发病平均年龄为 56±15 岁，SS 为 65.4±10.8 岁，51.4%为早期（IA-IIA），48.6%为晚期（IIB-IVA）CTCL。这些患者中，37.2%对阿利维 A 酯有反应，28.6%病情稳定，34.3%病情进展。阿利维 A 酯单独给药（25.7%）或联合五种伴随疗法（74.2%），最常与 ECP（31.4%）和 PUVA（11.4%）联合使用。63%的患者没有报告任何副作用，最常见的是高甘油三酯血症（20%）。
考虑到近三分之二的 CTCL 患者用阿利维 A 酯治疗后出现反应或病情稳定，与贝沙罗汀相比副作用少且成本低，阿利维 A 酯可能是治疗较不严重 CTCL 的潜在替代药物。该调查代表了在欧洲患者群体中用维甲酸阿利维 A 酯治疗 CTCL 记录的最大数量的治疗方法。
